Adds tianeptine sodium to list of Schedule II of controlled substances.
Summary
This bill amends New York’s Public Health Law to add tianeptine sodium to Schedule II of controlled substances. In practical terms, it would place tianeptine sodium under the state’s most tightly regulated controlled-substance categories, meaning its manufacture, distribution, possession, and prescribing would be subject to the restrictions that apply to Schedule II drugs.
The bill is narrow in scope and does not create a new regulatory framework beyond the scheduling change itself. It would take effect 90 days after becoming law, giving the state time to implement the reclassification and for regulated parties to adjust compliance practices.
Impact
By adding tianeptine sodium to Schedule II in section 3306 of the Public Health Law, the bill would change the substance’s legal status in New York and subject it to stricter controls, enforcement, and potential criminal penalties associated with Schedule II substances. The affected parties would include pharmacies, prescribers, distributors, manufacturers, law enforcement, and individuals possessing or using the substance. The bill would also align state law with a more restrictive approach to a substance that has raised public health and misuse concerns.
Sentiment
The available record shows no committee debate, votes, or recorded opposition, so there is no documented split in sentiment from the materials provided. Based on the bill’s straightforward public-health framing, the measure appears to be presented as a protective controlled-substance action rather than a controversial policy expansion. The absence of discussion suggests the bill was introduced in a technical or precautionary posture.
Contention
No specific points of contention are documented in the provided transcripts or voting history. In general, bills scheduling a substance more restrictively can raise concerns about whether the classification is proportionate, whether it could affect legitimate medical or research use, and how enforcement would be carried out. However, none of those issues are attributed to any legislator or stakeholder in the materials provided.